Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Teva Specialty Pharmaceuticals, the US respiratory therapy unit of Teva Pharmaceutical Industries and UCB have signed an agreement to co-commercialize Teva's US respiratory medicines.
Subscribe to our email newsletter
The initial product to be jointly promoted in the US is Teva’s ProAirHFA (albuterol sulfate) inhalation aerosol. Additionally, the agreement will provide UCB future joint promotion opportunities with other products in development by Teva Specialty Pharmaceuticals.
William Marth, president and CEO of Teva North America, said: “The respiratory therapy area has been identified as a key growth area given the incidence of asthma, allergic rhinitis, and COPD (chronic obstructive pulmonary disease). Our collaboration with UCB will help us achieve a stronger presence in this growing therapeutic area.”